Genedrive PLC Total Voting Rights (8296Q)
October 20 2023 - 4:52AM
UK Regulatory
TIDMGDR
RNS Number : 8296Q
Genedrive PLC
20 October 2023
genedrive plc
("genedrive" or the "Company")
Application for Listing
Total Voting Rights
genedrive plc (AIM: GDR), the point of care molecular
diagnostics company, confirms that in order to support the further
drawdown and delivery of its GBP5M Equity Prepayment facility that
was announced on 31 March 2023, application has been made for the
Admission to trading on AIM of 3,240,000 new Ordinary Shares of
1.5p each ("New Ordinary Shares"). Admission of the New Ordinary
Shares ("Admission") is expected to occur on 25 October 2023.
Following Admission, the New Ordinary Shares will rank pari passu
in all respects with the Company's existing ordinary shares.
Following Admission the Company's issued share capital will
consist of 108,439,946 Ordinary Shares of 1.5p each and this figure
may be used by shareholders as the denominator for the calculations
by which they should determine if they are required to notify their
interest in, or change to their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.
For further details please contact:
genedrive plc +44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
Cavendish Capital Markets Ltd (Joint
Broker) +44 (0)20 7220 0500
Geoff Nash
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com ) genedrive
plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The company are currently developing a genetic test
for CYP2C19 metaboliser status.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRNKKBPCBDKKKB
(END) Dow Jones Newswires
October 20, 2023 05:52 ET (09:52 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024